Limited-stage small cell lung carcinoma
Overview of limited-stage small cell lung carcinoma
Limited-stage small cell lung carcinoma[edit | edit source]
Limited-stage small cell lung carcinoma (LS-SCLC) is a classification of small cell lung carcinoma (SCLC), a highly aggressive form of lung cancer. In LS-SCLC, the cancer is confined to one side of the chest and can be encompassed within a single radiation field. This stage is distinct from extensive-stage small cell lung carcinoma, where the cancer has spread beyond the chest.
Pathophysiology[edit | edit source]
Small cell lung carcinoma is characterized by small, oval-shaped cancer cells that proliferate rapidly. These cells are derived from neuroendocrine cells in the lung and are known for their high mitotic index and tendency to metastasize early. The limited-stage designation indicates that the tumor is localized, typically involving the lung, mediastinum, and supraclavicular lymph nodes on the same side.
Diagnosis[edit | edit source]
The diagnosis of LS-SCLC involves a combination of imaging studies, such as chest X-ray, computed tomography (CT) scans, and positron emission tomography (PET) scans, to determine the extent of the disease. A biopsy is essential to confirm the diagnosis, often obtained via bronchoscopy or CT-guided needle biopsy. The histological examination reveals small, round, blue cells with scant cytoplasm, characteristic of SCLC.
Treatment[edit | edit source]
The primary treatment for LS-SCLC is a combination of chemotherapy and radiation therapy. Chemotherapy typically includes platinum-based drugs such as cisplatin or carboplatin, combined with etoposide. Concurrent radiation therapy to the chest is administered to improve local control and survival rates. Prophylactic cranial irradiation (PCI) may be offered to prevent metastasis to the brain, a common site of spread in SCLC.
Prognosis[edit | edit source]
The prognosis for patients with LS-SCLC is generally better than for those with extensive-stage disease, but it remains poor compared to other types of lung cancer. The median survival for LS-SCLC is approximately 15 to 20 months, with a 5-year survival rate of about 20%. Early detection and aggressive treatment are crucial for improving outcomes.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
